UK approves Moderna’s bivalent COVID-19 vaccine
MHRA approves Moderna’s adapted COVID-19 vaccine, Spikevax bivalent Original/Omicron, for use as a booster.
List view / Grid view
MHRA approves Moderna’s adapted COVID-19 vaccine, Spikevax bivalent Original/Omicron, for use as a booster.
With vaccination programmes fighting to recover after the pandemic fuelled the “largest backslide” in three decades, GSK says manufacturing challenges will leave a shortage of rotavirus vaccines.
A new method of mucosal vaccine delivery that uses albumin to help transport vaccine antigens could lead to better vaccines for HIV and COVID-19.
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
In this article, EPR’s Hannah Balfour discusses the recent multi-country monkeypox outbreak, highlighting key developments in the international response.
Innovations in the use of viral vectors as a gene delivery vehicle are a key factor in the growth of the gene and cell therapy field.
Phase I human challenge study shows a single subcutaneous injection of the monoclonal antibody L9LS provides at least short-term protection against malaria.
Why do pharmaceutical manufacturers still believe older methods are reliable for quality testing when there’s superior technology available on the market?
US and European Pharmacopoeias announce new activities to help promote vaccine development, manufacturing, quality and supply.
Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.
New agreement reserves million doses of GSK’s pandemic influenza vaccine Adjupanrix to support Europe’s pandemic preparedness.
Phase II results suggest litifilimab safely and effectively reduces skin disease activity in cutaneous lupus erythematosus (CLE) patients.
New research suggests microparticles able to release their payloads at different times could form the basis of self-boosting vaccine courses that would require just a single injection.
The draft Regulation aims to enhance the protection of donors and recipients of substances of human origin (SoHO) therapies, while facilitating supply and innovation.
Study shows nicotinic acid (NA) to nicotinamide (NAM) ratio enables detection of early-stage microbial contaminations in cell therapy products.